Publications by authors named "Stephen Bracewell"
Background: Conventional transarterial chemoembolization (cTACE) has been the standard treatment for intermediate stage hepatocellular carcinoma (HCC). For early stage HCC, percutaneous ablation is a curative option. There is growing evidence to support combined therapy to improve tumor response and overall survival (OS) in patients with unresectable HCC.
View Article and Find Full Text PDFArticle Synopsis
- The study examined the safety, effectiveness, and prognostic factors of using conventional transarterial chemoembolization (c-TACE) with mitomycin in treating patients with unresectable hepatocellular carcinoma (HCC) from 2007 to 2012.
- Out of 60 patients, the overall survival (OS) rates were 72.1% at 1 year, 47.8% at 3 years, and 39.3% at 5 years, with a median OS of 15 months; a strong correlation was found between tumor response and risk of death.
- The findings indicated that c-TACE with mitomycin was both effective and safe, especially highlighting
Article Synopsis
- The study aimed to compare patient satisfaction between transradial access (TRA) and transfemoral access (TFA) for intra-arterial therapy in liver cancer patients.
- A total of 55 patients participated, with results showing that 81% preferred TRA over TFA, and TRA was associated with lower radiation exposure to the operator.
- No significant differences were found in complications, procedure time, contrast volume, or patient radiation exposure between the two access methods.